ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2278

Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
Abstract Number: 1675

Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)
Abstract Number: 0815

Neuropathic-like Pain Characteristics Predict Worse Pain Outcomes in Early Rheumatoid Arthritis: a Prospective Cohort Study with Embedded Neuroimaging Evaluation
Abstract Number: 2310

Neuropeptide influence in nociception and inflammation through immune system modulation in SPA patients
Abstract Number: 1295

Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Abstract Number: 0609

Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes
Abstract Number: 1208

Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
Abstract Number: 0723

Neutrophil and Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis: Phenotype-based Characterization and Response to Mepolizumab
Abstract Number: 1874

Neutrophil Extracellular Trap-Rich Systemic Sclerosis Plasma Promotes Microvascular Endothelial Cell Proliferation and Migration: Implications for Aberrant Angiogenesis
Abstract Number: 2078

Neutrophil Extracellular Traps from Patients with Idiopathic Inflammatory Myopathies Induce Interferogenic Responses in Macrophages and Myeloid Dendritic Cells
Abstract Number: 0134

Neutrophil Gasdermin D Pores as Potential Therapeutic Targets in APS-Associated Thromboinflammation
Abstract Number: 2700

Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome
Abstract Number: 2425

Neutrophil Transcriptomics in SLE: Exploring Intrinsic, Ex Vivo Adaptation, and CAR-T Cell Therapy-Induced Changes
Abstract Number: 2664

Neutrophil-to-Lymphocyte Ratio (NLR) as a Clinically Accessible Marker for Interferon Signatures in Autoimmune Diseases
Abstract Number: 0675

Neutrophil-to-Lymphocyte Ratio as a biomarker for disease onset and a predictor for mortality in Systemic Sclerosis – real-world data from a large healthcare provider in Israel.

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].